Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose 5% provides free water and calories for cellular metabolism, with glucose being the primary energy source. Sodium chloride 0.33% restores sodium and chloride ions to maintain extracellular fluid osmolality and acid-base balance. Potassium chloride 0.075% replenishes potassium, essential for nerve conduction, muscle contraction, and enzymatic reactions.
Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.
Intravenous replacement of fluid, electrolytes, and calories in patients unable to take orally,Maintenance fluid therapy for hydration and electrolyte balance,Treatment of hypokalemia when combined with potassium chloride
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases (e.g., emphysema, chronic bronchitis),Adjunctive therapy in acute bronchial asthma and status asthmaticus,Off-label: Treatment of apnea of prematurity
Intravenous infusion. Dose determined by fluid, electrolyte, and caloric requirements. Typical adult dose: 500-1000 m L as a single infusion at a rate of 100-200 m L/hour, based on clinical status.
Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.
Dextrose: <15 minutes (rapid cellular uptake and metabolism). Electrolytes: sodium and chloride have no defined half-life due to rapid distribution and renal regulation; potassium half-life approximately 1-1.5 hours in plasma following intravenous administration.
Terminal elimination half-life: 3-12 hours in adults (mean 5-6 hours); prolonged in hepatic impairment, heart failure, COPD, and neonates (up to 30 hours). Smoking reduces half-life by 30-50%.
Dextrose is metabolized via glycolysis and the Krebs cycle, primarily in the liver and peripheral tissues. Sodium and chloride are excreted renally with minimal metabolism. Potassium is excreted renally (90%) and fecally (10%), with active reabsorption in the distal tubules.
Theophylline is metabolized primarily in the liver by cytochrome P450 isoenzymes, predominantly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolism involves N-demethylation and oxidation. In neonates, metabolism is immature; in adults, ~90% is hepatically cleared. Ethylenediamine is minimally metabolized.
Dextrose: nearly completely metabolized to CO2 and water, with <1% excreted unchanged in urine. Sodium and chloride: primarily excreted renally, with >90% of filtered load reabsorbed; excretion varies with dietary intake and homeostatic mechanisms. Potassium: >90% excreted renally, with the remainder in feces and sweat.
Renal excretion of unchanged drug (about 10-20%) and metabolites (primarily 1,3-dimethyluric acid, 1-methyluric acid, 3-methylxanthine). Billary/fecal excretion is negligible.
Dextrose: negligible (<5%). Sodium and chloride: unbound. Potassium: negligible binding.
Theophylline (active moiety): approximately 40% bound to plasma proteins, primarily albumin. Protein binding decreases in neonates, hepatic cirrhosis, and uremia.
Dextrose: approximately 0.15-0.25 L/kg (extracellular fluid). Sodium: 0.1-0.2 L/kg (primarily extracellular). Chloride: similar to sodium. Potassium: 0.4-0.5 L/kg (distributes across total body water).
Apparent volume of distribution: approximately 0.4-0.6 L/kg (average 0.45 L/kg). Indicates distribution into total body water; slightly higher in neonates and premature infants.
Intravenous: 100% for all components.
Oral: 96-100% for immediate-release tablets; 50-70% for some sustained-release formulations depending on formulation. Rectal: 70-80% (variable). IV: 100%.
Use with caution in renal impairment. For GFR 10-50 m L/min, reduce potassium content or use with caution; for GFR <10 m L/min, avoid potassium-containing solutions unless hypokalemia is present. Monitor serum potassium frequently.
No dose adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: reduce maintenance dose by 50% and monitor serum theophylline levels. For GFR <10 m L/min: reduce maintenance dose by 50% and extend dosing interval or use with caution.
No specific dose adjustment required for Child-Pugh A or B. For Child-Pugh C, monitor glucose and electrolytes due to altered metabolism; consider dextrose content and potassium load.
Child-Pugh A: reduce dose by 50%. Child-Pugh B: reduce dose by 75%. Child-Pugh C: contraindicated or use with extreme caution, reduce dose by 80% and monitor levels.
Dose based on weight: 5-20 m L/kg per infusion, titrated to clinical need. Maximum infusion rate: 0.5 g/kg/hour of dextrose. Potassium dose: 0.5-1 m Eq/kg/day, not to exceed 3 m Eq/kg/day. Monitor serum electrolytes.
Loading dose: 1 mg/kg IV (if not on theophylline). Maintenance: Continuous infusion: age 6 months-1 year: 0.5 mg/kg/h; age 1-9 years: 0.8 mg/kg/h; age 9-12 years: 0.7 mg/kg/h; age 12-16 years: 0.6 mg/kg/h. Maximum daily dose: 24 mg/kg/day.
Use with caution due to potential for fluid overload, electrolyte imbalance, or glucose intolerance. Start with lower infusion rates (50-100 m L/hour) and monitor renal function, serum potassium, and blood glucose closely.
Consider lower initial doses due to decreased clearance. Use ideal body weight. Start at lower maintenance infusion rate (e.g., 0.3 mg/kg/h) and titrate based on serum levels and clinical response. Monitor for toxicity.
None
None
Risk of hyperglycemia in diabetic patients or those with glucose intolerance,Hyperkalemia may occur in patients with renal impairment or when potassium is administered rapidly,Fluid overload in patients with congestive heart failure or renal insufficiency,Electrolyte imbalances (hypernatremia, hyponatremia, hyperchloremia) require monitoring,Extravasation may cause tissue necrosis
Narrow therapeutic index; serum theophylline levels must be monitored to avoid toxicity. Risk of seizures, cardiac arrhythmias, and death, especially at high serum concentrations. Caution in patients with hepatic impairment, congestive heart failure, cor pulmonale, fever, and in the elderly. Drug interactions with cimetidine, fluoroquinolones, macrolides, oral contraceptives, and other CYP1A2 inhibitors can increase toxicity.
Hyperkalemia or severe renal impairment with potassium retention,Hypertonic dehydration or severe hyponatremia (with this specific formulation),Anuria or severe renal failure,Acute myocardial infarction (high potassium may worsen arrhythmias),Addison's disease (risk of hyperkalemia)
Absolute: Hypersensitivity to theophylline, ethylenediamine, or any component; use in patients with active seizure disorder (unless receiving appropriate anticonvulsant therapy); use in patients with a history of ventricular arrhythmias (except under close supervision). Relative: Peptic ulcer disease, hyperthyroidism, hypertension, and renal impairment.
No direct food interactions. Dextrose provides calories (3.4 kcal/g) and may affect blood glucose; diabetic patients may require insulin adjustment. Avoid excessive dietary potassium intake while receiving this solution. No specific alcohol interaction.
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they can potentiate theophylline effects and increase risk of toxicity. A high-protein diet may increase theophylline clearance; maintain consistent dietary habits.
No known teratogenic risk. Dextrose, sodium chloride, and potassium chloride are normal constituents of body fluids; no evidence of fetal harm at standard infusion rates. Use in pregnancy only if clearly needed.
Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only if benefit outweighs risk; may cause fetal tachycardia or irritability due to adenosine receptor blockade. Avoid near term due to potential neonatal irritability.
Excreted into breast milk in negligible amounts; M/P ratio not established. Compatible with breastfeeding; monitor infant for electrolyte imbalances if high doses given to mother.
Not recommended unless essential. Aminophylline is excreted into breast milk; M/P ratio approximately 0.6–0.8. Monitor infant for irritability or insomnia. Consider alternative therapies if breastfeeding.
No specific dose adjustment required in pregnancy based on pharmacokinetics. Use standard clinical dosing guided by electrolyte needs and fluid status.
Pregnancy may decrease protein binding and increase clearance of theophylline; monitor serum levels closely. Dose may need to be increased by 10–30% to maintain therapeutic levels. Postpartum, doses may need reduction.
This fixed-combination solution provides 5% dextrose (3.4 kcal/g), sodium 14 m Eq/L, chloride 19 m Eq/L, and potassium 10 m Eq/L. Osmolarity ~308 m Osm/L. Useful for maintenance or replacement when mild potassium depletion coexists with hyponatremia or hypochloremia. Monitor serum potassium and renal function; avoid in severe hyperkalemia, renal failure, or hyperglycemia. Not for initial resuscitation of hypovolemia due to hypotonicity. Check IV site for phlebitis.
Aminophylline is a bronchodilator used primarily for asthma and COPD exacerbations. Monitor serum theophylline levels closely due to narrow therapeutic index (10-20 mcg/m L). Administer IV infusion over 30 minutes to avoid hypotension. Caution in patients with cardiac arrhythmias, hyperthyroidism, or seizure disorders. Drug interactions include cimetidine, fluoroquinolones, and macrolides which increase theophylline levels.
This solution provides sugar (dextrose), salt, and potassium. It is given intravenously to maintain fluid balance and electrolyte levels. Report any pain, redness, or swelling at the IV site. Notify your provider if you experience chest pain, irregular heartbeat, or muscle weakness.,Do not suddenly stop the infusion without medical advice. This product may affect blood sugar levels if you have diabetes.,Inform your doctor if you have kidney disease, heart disease, or are on a potassium-restricted diet.
Take this medication exactly as prescribed; do not stop or change dose without consulting your doctor.,Avoid excessive caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects like jitteriness and palpitations.,Report any symptoms of toxicity such as nausea, vomiting, insomnia, rapid heart rate, or seizures immediately.,Inform your healthcare provider of all other medications, especially antibiotics, heart medications, or seizure drugs.,Do not chew or crush the solution; it is for intravenous use only under medical supervision.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, answered by our medical review team.
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER is a Electrolyte that works by Dextrose 5% provides free water and calories for cellular metabolism, with glucose being the primary energy source. Sodium chloride 0.33% restores sodium and chloride ions to maintain extracellular fluid osmolality and acid-base balance. Potassium chloride 0.075% replenishes potassium, essential for nerve conduction, muscle contraction, and enzymatic reactions.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER is: Intravenous infusion. Dose determined by fluid, electrolyte, and caloric requirements. Typical adult dose: 500-1000 m L as a single infusion at a rate of 100-200 m L/hour, based on clinical status.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER is classified as Category A/B. No known teratogenic risk. Dextrose, sodium chloride, and potassium chloride are normal constituents of body fluids; no evidence of fetal harm at standard infusion rates. Use in pr. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.